Pharma Journalist -

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion on a dosing and administration label update for…
Read More...

ImaginAb Inc. announced that it has signed a multi-year non-exclusive license agreement with AstraZeneca. Under the terms of the agreement, ImaginAb's CD8 ImmunoPET technology will…
Read More...

Altimmune, Inc., announced that it is launching a collaboration with the University of Alabama at Birmingham (UAB) on the development of its single-dose, intranasal COVID-19 vaccine,…
Read More...

Noveome Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing next-generation biologics for the promotion and restoration of cellular integrity of inflamed or…
Read More...

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced it has been…
Read More...

Aptorum Group Limited, a biopharmaceutical company focused on the development of novel therapeutics for unmet needs including but not limited to infectious, orphan and metabolic disease…
Read More...

Cobra Biologics and the Karolinska Institutet announced they have been awarded €3million emergency funding by Horizon 2020 for research and development, and phase I clinical trial…
Read More...

Sorrento Therapeutics, Inc. announced it has entered into a research testing agreement with The University of Texas Medical Branch at Galveston for the preclinical testing of Sorrento’s…
Read More...

AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with…
Read More...

Ryvu Therapeutics, a clinical-stage biopharmaceutical company developing novel small molecule therapies that address emerging targets in oncology, announced that the U.S. Food and Drug…
Read More...